Xiyu Dai

No. 180, Fenglin Road
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

USP20 mediates malignant phenotypic changes in bladder cancer through direct interactions with YAP1.

USP20 mediates malignant phenotypic changes in bladder cancer through direct interactions with YAP1.

Journal: Neoplasia (New York, N.Y.)
Published: July 08, 2024

Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment.

Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment.

Journal: Cell death & disease
Published: April 17, 2023

Correction to: Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.

Correction to: Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.

Journal: British journal of cancer
Published: March 21, 2023

CircDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.

CircDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.

Journal: Epigenetics
Published: February 25, 2023

Correction: Autophagy-associated circular RNA hsa_circ_0007813 modulates human bladder cancer progression via hsa-miR-361-3p/IGF2R regulation.

Correction: Autophagy-associated circular RNA hsa_circ_0007813 modulates human bladder cancer progression via hsa-miR-361-3p/IGF2R regulation.

Journal: Cell death & disease
Published: February 13, 2023

Correction to: High-throughput sequencing identified circular RNA circUBE2K mediating RhoA associated bladder cancer phenotype via regulation of miR-516b-5p/ARHGAP5 axis.

Correction to: High-throughput sequencing identified circular RNA circUBE2K mediating RhoA associated bladder cancer phenotype via regulation of miR-516b-5p/ARHGAP5 axis.

Journal: Cell death & disease
Published: December 22, 2022

Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study.

Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study.

Journal: Frontiers in nutrition
Published: August 01, 2022

Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.

Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.

Journal: British journal of cancer
Published: July 15, 2022

The potential mechanism of Longsheyangquan Decoction on the treatment of bladder cancer: Systemic network pharmacology and molecular docking.

The potential mechanism of Longsheyangquan Decoction on the treatment of bladder cancer: Systemic network pharmacology and molecular docking.

Journal: Frontiers in pharmacology
Published: June 10, 2022

Identification and validation of a poor clinical outcome subtype of primary prostate cancer with Midkine abundance.

Identification and validation of a poor clinical outcome subtype of primary prostate cancer with Midkine abundance.

Journal: Cancer science
Published: March 17, 2022

Circ-AFAP1 promote clear cell renal cell carcinoma growth and angiogenesis by the Circ-AFAP1/miR-374b-3p/VEGFA signaling axis.

Circ-AFAP1 promote clear cell renal cell carcinoma growth and angiogenesis by the Circ-AFAP1/miR-374b-3p/VEGFA signaling axis.

Journal: Cell death discovery
Published: November 08, 2021

Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments.

Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 16, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026